SynthesisMedicina oral, patologia oral y cirugia bucal2023
Leukocyte and platelet rich fibrin in the management of medication-related osteonecrosis of the jaw: A systematic review and meta-analysis.
Synthesis in Medicina oral, patologia oral y cirugia bucal, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Comparison between different intermaxillary fixation systems in the surgical and orthopedic treatment of non-condylar mandibular fractures. Systematic review.Medicina oral, patologia oral y cirugia bucal · 2025Pooled it
- Regeneration of periodontal intrabony defects using platelet-rich fibrin (PRF): a systematic review and network meta-analysis.Odontology · 2024Pooled it
- A scoping review on platelet-rich fibrin-driven bone regeneration: biological mechanisms and clinical applications in oral and maxillofacial surgery.Journal of the Korean Association of Oral and Maxillofacial Surgeons · 2026Article
- Advanced Platelet-Rich Fibrin in Surgical Management of Medication-Related Osteonecrosis of the Jaw: A Prospective Case Series Study.Clinical and experimental dental research · 2026Article
- Efficacy of leukocyte- and platelet-rich fibrin in the treatment and prevention of medication-related osteonecrosis of the jaw: a prospective study.Medicina oral, patologia oral y cirugia bucal · 2025Article
- Surgery with leukocyte and platelet-rich fibrin (L-PRF) vs. surgery alone for medication-related osteonecrosis of the jaw: A randomized controlled trial.Journal of clinical and experimental dentistry · 2025Article
- Autologous platelet concentrates as adjuvant in the surgical management of medication-related osteonecrosis of the jaw.Periodontology 2000 · 2025Review
- Beyond the clot: how the biomolecular landscape of platelet-rich fibrin directs fibroblast functions.Frontiers in oral health · 2025Review
- Advances in Regenerative Medicine for the Treatment of Osteonecrosis of the Jaw.Galen medical journal · 2024Review
- Application of Platelet-Rich Fibrin and Bone Morphogenetic Protein for Full-Mouth Implant-Based Oral Rehabilitation in a Case of Mandibular Osteoradionecrosis.Case reports in dentistry · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOsteonecrosis of the jaw (ONJ) has a frequent adverse effect after the administration of nitrogenous bisphosphonates, as non-nitrogenous bisphosphonates are metabolized more rapidly and would produce this effect to a lesser extent. The objective of this study is to analyze the results obtained in the literature with the use of L-PRF in the treatment of ONJ through a systematic review and meta-analysis. MATERIAL AND
methodsMedline (via PubMed), Cochrane, Web of Science and Grey Literature Database was screened from which 10 were selected.
resultsIn the meta-analysis with full resolution, combining the use of L-PRF in the treatment of ONJ, a weighted proportion (PP) of 94.3% of complete resolution is obtained (95% CI: 91.2-97.4, p<0.001), with a low degree of heterogeneity, statistically significant (I2 = 29.02%; p<0.001). When analyzing the non-resolution data, a weighted proportion (PP) of 7.7% (95% CI: 3.6-11.9; p<0.001) was obtained with moderate heterogeneity (I2: 41.87%; p=0.112). In the meta-regression, no significant correlation was found between complete resolution and year of publication (intercept = 2.88, p=0.829). In consistency analysis no major changes in PP are identified when any of the studies are eliminated, demonstrating a high reliability in the combined results.
conclusionL-PRF alone or in combination with other therapies in treatment of ONJ achieved high percentages of complete lesion resolution (94.3%). In studies where L-PRF is combined with other therapies, and where the effectiveness of the other therapy alone is analyzed, L-PRF has been shown higher percentages of resolution.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.